Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background Exercise is recommended as a cornerstone of treatment for type 2 diabetes mellitus (T2DM), however, it is often poorly adopted by patients. Even in the absence of apparent cardiovascular disease, persons with T2DM have an impaired ability to carry out maximal and submaximal exercise and these impairments are correlated with cardiac and endothelial dysfunction. Glucagon-like pepetide-1 (GLP-1) augments endothelial and cardiac function in T2DM. We hypothesized that administration of a GLP-1 agonist (exenatide) would improve exercise capacity in T2DM. Methods and Results Twenty-three participants (64±4 years; mean±SE) with uncomplicated T2DM were randomized in a double-blinded manner to receive either 10mcg BID of exenatide or matching placebo after baseline measurements. Treatment with exenatide did not improve VO2peak (P=0.1464) or VO2 kinetics (P=0.2775). Diastolic function, assessed via resting lateral E:E’, was improved with administration of exenatide compared with placebo (Placebo Pre: 7.6±1.0 vs. Post: 8.4±1.2 vs. Exenatide Pre: 8.1±0.7 vs. Post: 6.7±0.6; P=0.0127). Additionally, arterial stiffness measured by pulse wave velocity, was reduced with exenatide treatment compared with placebo (Placebo Pre: 10.5±0.8 vs. Post: 11.5±1.1 seconds vs. Exenatide Pre: 11.4±1.8 vs. Post: 10.2±1.4 seconds; P=0.0373). Exenatide treatment did not improve endothelial function (P=0.1793). Conclusions Administration of exenatide improved cardiac function and reduced arterial stiffness, however, these changes were not accompanied by improved functional exercise capacity. In order to realize the benefits of this drug on exercise capacity, combining exenatide with aerobic exercise training in participants with T2DM may be warranted. Clinical Trials Registration www.clinicaltrials.gov NCT01364584
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“…may have relevance to recent clinical investigations that report decreased all-cause and cardiovascular mortality and decreased incidence of myocardial infarction with other GLP-1 receptor agonists in patients with T2DM (liraglutide (Marso & Daniels, 2016) and semaglutide (Steg & Roussel, 2016)).”
BackgroundPHYSICAL ACTIVITY ASSESSMENT METHODOLOGY IN THE FIVE-CITY PROJECT1
SALLIS, J. F., HASKELL, W. L., WOOD, P. D., FORTMANN, S. P., ROGERS, T., BLAIR, S. N., & PAFFENBARGER, R. S. (1985) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113987 · Cited by 1,716
AMPK and PPARδ Agonists Are Exercise Mimetics
Narkar, V. A., Downes, M., Yu, R. T., Embler, E., Wang, Y.-X., Banayo, E., Mihaylova, M. M., Nelson, M. C., Zou, Y., Juguilon, H., et al. (2008) · Cell · doi:10.1016/j.cell.2008.06.051 · Cited by 1,222
Wei, M. (1999) · JAMA · doi:10.1001/jama.282.16.1547 · Cited by 1,168 · cited 2×
“Exercise capacity is a potent predictor of cardiovascular and all-cause mortality (Wei et al., 1999; 2000).”
BackgroundNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 2×
“Previous investigations of GLP-1 have demonstrated improvement of left ventricular systolic and diastolic function in humans, rodents, and canines (Luque, 2002; Nikolaidis et al., 2004b; 2004a; Nikolaidis, 2005; Zhao et al., 2006; Sokos et al., 2007; Mafong & Henry, 2009).”
BackgroundResultThe role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
Nikolaidis, L. A., Elahi, D., Shen, Y.-T., & Shannon, R. P. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00347.2005 · Cited by 274 · cited 2×
“Previous investigations of GLP-1 have demonstrated improvement of left ventricular systolic and diastolic function in humans, rodents, and canines (Luque, 2002; Nikolaidis et al., 2004b; 2004a; Nikolaidis, 2005; Zhao et al., 2006; Sokos et al., 2007; Mafong & Henry, 2009).”
BackgroundResultKoska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174 · cited 2×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript Koska et al., 2015); this mechanism could theoretically lead to improved exercise capacity and reduced CVD risk.”
BackgroundGlucoregulation and hormonal responses to maximal exercise in non-insulin-dependent diabetes
Kjaer, M., Hollenbeck, C. B., Frey-Hewitt, B., Galbo, H., Haskell, W., & Reaven, G. M. (1990) · Journal of Applied Physiology · doi:10.1152/jappl.1990.68.5.2067 · Cited by 171
Chai, W., Zhang, X., Barrett, E. J., & Liu, Z. (2014) · Diabetes · doi:10.2337/db13-1597 · Cited by 73 · cited 4×
“It is well established that GLP-1 improves blood flow to skeletal muscle via increases in endothelial and cardiac function in T2DM (Ceriello et al., 2006; Mafong & Henry, 2009; Chai et al., 2014).”
BackgroundResultInfluential
Cited by
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
Lambadiari, V., Pavlidis, G., Kousathana, F., Varoudi, M., Vlastos, D., Maratou, E., Georgiou, D., Andreadou, I., Parissis, J., Triantafyllidi, H., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0646-z · Cited by 146
“A 3-months’ exenatide delivery to sedentary patients with uncomplicated, although not treatment-naive, type 2 diabetes, has recently shown to improve cardiac function and reduce arterial stiffness, although it proved neutral in terms of functional exercise capacity and endothelial function [31].”
BackgroundVosoughi, K., Atieh, J., Khanna, L., Khoshbin, K., Prokop, L. J., Davitkov, P., Murad, M. H., & Camilleri, M. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101213 · Cited by 97
The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF
Withaar, C., Meems, L. M. G., Nollet, E. E., Schouten, E. M., Schroeder, M. A., Knudsen, L. B., Niss, K., Madsen, C. T., Hoegl, A., Mazzoni, G., et al. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2023.05.012 · Cited by 74
Vosoughi, K., Salman Roghani, R., & Camilleri, M. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100456 · Cited by 65
Metadata
- Authors
- Scalzo, R. L., Moreau, K. L., Ozemek, C., Herlache, L., McMillin, S., Gilligan, S., Huebschmann, A. G., Bauer, T. A., Dorosz, J., Reusch, J. E. B., & Regensteiner, J. G.
- Venue
- Journal of Diabetes and its Complications
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 31
- Issue
- 2
- Pages
- 449-455
- ISSN
- 0891-6632 (ISSN-L)
- 1056-8727
- OpenAlex
- W2529813822
- Cited by
- 72
- References
- 11
- FWCI
- 6.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.